Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
40
ABEO Quote, Financials, Valuation and Earnings
Last price:
$5.13
Seasonality move
:
284.65%
Day range:
$4.93 - $5.16
52-week range:
$3.93 - $7.54
Dividend yield:
0%
P/E ratio:
4.40x
P/S ratio:
693.53x
P/B ratio:
1.62x
Volume:
878.7K
Avg. volume:
1.2M
1-year change:
-12.76%
Market cap:
$278M
Revenue:
--
EPS (TTM):
$1.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
$5.6M | -$0.34 | -97.62% | -57.23% | $20.64 |
|
CLDX
Celldex Therapeutics, Inc.
|
$643.3K | -$1.09 | -6.19% | -30.43% | $53.36 |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- |
|
NUWE
Nuwellis, Inc.
|
$2.2M | -- | 9.98% | -- | $13.00 |
|
PAVM
PAVmed, Inc.
|
$98K | -$4.20 | -100% | -78.99% | $9.50 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.6M | -$0.03 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
$5.13 | $20.64 | $278M | 4.40x | $0.00 | 0% | 693.53x |
|
CLDX
Celldex Therapeutics, Inc.
|
$23.80 | $53.36 | $1.6B | -- | $0.00 | 0% | 607.70x |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NUWE
Nuwellis, Inc.
|
$2.61 | $13.00 | $18.2M | -- | $0.00 | 0% | 0.70x |
|
PAVM
PAVmed, Inc.
|
$10.80 | $9.50 | $10M | 0.30x | $0.00 | 0% | 5,045.37x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.26 | $5.50 | $35.7M | -- | $0.00 | 0% | 4.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -1.035 | 8.71% | 9.35x |
|
CLDX
Celldex Therapeutics, Inc.
|
0.44% | 1.179 | 0.15% | 12.42x |
|
CV
Central Vermont Public Service Corp.
|
-- | 0.000 | -- | -- |
|
NUWE
Nuwellis, Inc.
|
8.91% | -2.261 | 1.64% | 1.20x |
|
PAVM
PAVmed, Inc.
|
20.6% | -0.669 | 34.03% | 0.30x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
CLDX
Celldex Therapeutics, Inc.
|
-$824K | -$73.6M | -32.02% | -32.17% | -8747.53% | -$49.1M |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- | -- |
|
NUWE
Nuwellis, Inc.
|
$1.4M | -$2.7M | -773.58% | -1004.06% | -121.65% | -$3.2M |
|
PAVM
PAVmed, Inc.
|
-$72K | -$4.8M | 4.06% | 8.75% | -96880% | -$899K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Abeona Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ABEO or CLDX?
Celldex Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -7753.43%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M -
What do Analysts Say About ABEO or CLDX?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 302.4%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.36 which suggests that it could grow by 124.19%. Given that Abeona Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 CLDXCelldex Therapeutics, Inc.12 2 0 -
Is ABEO or CLDX More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.242, suggesting its more volatile than the S&P 500 by 24.182%.
-
Which is a Better Dividend Stock ABEO or CLDX?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or CLDX?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.40x while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 693.53x versus 607.70x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.693.53x 4.40x -- -$5.2M CLDXCelldex Therapeutics, Inc.607.70x -- -- -$67M
-
Which has Higher Returns ABEO or CV?
Central Vermont Public Service Corp. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of --. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Central Vermont Public Service Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M CVCentral Vermont Public Service Corp.-- -- -- -
What do Analysts Say About ABEO or CV?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 302.4%. On the other hand Central Vermont Public Service Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Abeona Therapeutics, Inc. has higher upside potential than Central Vermont Public Service Corp., analysts believe Abeona Therapeutics, Inc. is more attractive than Central Vermont Public Service Corp..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 CVCentral Vermont Public Service Corp.0 0 0 -
Is ABEO or CV More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Central Vermont Public Service Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ABEO or CV?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Central Vermont Public Service Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Central Vermont Public Service Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or CV?
Abeona Therapeutics, Inc. quarterly revenues are --, which are larger than Central Vermont Public Service Corp. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Central Vermont Public Service Corp.'s net income of --. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.40x while Central Vermont Public Service Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 693.53x versus -- for Central Vermont Public Service Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.693.53x 4.40x -- -$5.2M CVCentral Vermont Public Service Corp.-- -- -- --
-
Which has Higher Returns ABEO or NUWE?
Nuwellis, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of 21.11%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Nuwellis, Inc.'s return on equity of -1004.06%.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M NUWENuwellis, Inc.65.18% $0.56 $4.3M -
What do Analysts Say About ABEO or NUWE?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 302.4%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 17601.17%. Given that Nuwellis, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Nuwellis, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 NUWENuwellis, Inc.0 1 0 -
Is ABEO or NUWE More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.106, suggesting its less volatile than the S&P 500 by 110.586%.
-
Which is a Better Dividend Stock ABEO or NUWE?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or NUWE?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Nuwellis, Inc. quarterly revenues of $2.2M. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Nuwellis, Inc.'s net income of $468K. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.40x while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 693.53x versus 0.70x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.693.53x 4.40x -- -$5.2M NUWENuwellis, Inc.0.70x -- $2.2M $468K
-
Which has Higher Returns ABEO or PAVM?
PAVmed, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -120220%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat PAVmed, Inc.'s return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M PAVMPAVmed, Inc.-1440% -$0.29 $35.1M -
What do Analysts Say About ABEO or PAVM?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 302.4%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 2538.89%. Given that PAVmed, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe PAVmed, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 PAVMPAVmed, Inc.1 0 0 -
Is ABEO or PAVM More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.118, suggesting its more volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock ABEO or PAVM?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or PAVM?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.40x while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 693.53x versus 5,045.37x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.693.53x 4.40x -- -$5.2M PAVMPAVmed, Inc.5,045.37x 0.30x $5K -$6M
-
Which has Higher Returns ABEO or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -316.61%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About ABEO or PSTV?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 302.4%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Plus Therapeutics, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is ABEO or PSTV More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock ABEO or PSTV?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or PSTV?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.40x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 693.53x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.693.53x 4.40x -- -$5.2M PSTVPlus Therapeutics, Inc.4.17x -- $1.4M -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
